Analyst Ratings for [INCY] Incyte Corporation

8/6/25	Upgrades	Eq Weight Overweight	X
INCY Incyte Wells Fargo
$89
8/1/25	Initiated	Overweight	X
INCY Incyte Barclays
$90
6/16/25	Upgrades	Hold Buy	X
INCY Incyte Stifel
$107
3/18/25	Downgrades	Buy Neutral	X
INCY Incyte Guggenheim
3/18/25	Downgrades	Outperform Mkt Perform	X
INCY Incyte William Blair
12/17/24	Initiated	Neutral	X
INCY Incyte UBS
$77
10/29/24	Upgrades	Neutral Buy	X
INCY Incyte BofA Securities
$68 $90
10/1/24	Initiated	Outperform	X
INCY Incyte Wolfe Research
$84
9/18/24	Downgrades	Buy Hold	X
INCY Incyte Truist
$83 $74
7/2/24	Downgrades	Mkt Perform Underperform	X
INCY Incyte BMO Capital Markets
$52 $48
5/23/24	Initiated	Hold	X
INCY Incyte Deutsche Bank
$55
4/23/24	Initiated	Neutral	X
INCY Incyte Cantor Fitzgerald
2/23/24	Initiated	Buy	X
INCY Incyte Jefferies
$81
2/14/24	Downgrades	Mkt Outperform Mkt Perform	X
INCY Incyte JMP Securities
12/13/23	Upgrades	Mkt Perform Outperform	X
INCY Incyte Leerink Partners
$78
12/4/23	Upgrades	Neutral Buy	X
INCY Incyte Guggenheim
$86
11/21/23	Downgrades	Buy Neutral	X
INCY Incyte Goldman
$98 $65
7/25/23	Initiated	Buy	X
INCY Incyte Citigroup
$82
5/4/23	Downgrades	Buy Neutral	X
INCY Incyte BofA Securities
$84
4/10/23	Downgrades	Outperform Sec Perform	X
INCY Incyte RBC Capital Mkts
$81 $79
3/24/23	Upgrades	Underperform Mkt Perform	X
INCY Incyte SVB Securities
$61
1/31/23	Initiated	Overweight	X
INCY Incyte Piper Sandler
$100
8/3/22	Downgrades	Outperform In-line	X
INCY Incyte Evercore ISI
$90 $78
8/3/22	Downgrades	Buy Neutral	X
INCY Incyte Guggenheim
7/28/22	Initiated	Equal Weight	X
INCY Incyte Wells Fargo
$76
2/9/22	Downgrades	Mkt Perform Underperform	X
INCY Incyte SVB Leerink
$60 $56
1/18/22	Upgrades	Sec Perform Outperform	X
INCY Incyte RBC Capital Mkts
$78 $90
11/19/21	Initiated	Market Perform	X
INCY Incyte BMO Capital Markets
$75
7/20/21	Upgrades	Hold Buy	X
INCY Incyte The Benchmark Company
$89
2/10/21	Downgrades	Mkt Perform Underperform	X
INCY Incyte SVB Leerink
$70
1/7/21	Initiated	Buy	X
INCY Incyte Truist
$120
1/4/21	Upgrades	Neutral Buy	X
INCY Incyte Guggenheim
5/21/19	Initiated	Neutral	X
INCY Incyte Credit Suisse
$75
5/3/19	Downgrades	Overweight Eq Weight	X
INCY Incyte Barclays
$90 $82
4/11/19	Initiated	Hold	X
INCY Incyte Stifel
$82
4/3/19	Downgrades	Outperform Sec Perform	X
INCY Incyte RBC Capital Mkts
$89
1/24/19	Upgrades	Hold Buy	X
INCY Incyte Gabelli & Co
$105
1/24/19	Upgrades	Mkt Perform Outperform	X
INCY Incyte William Blair
1/16/19	Downgrades	Buy Neutral	X
INCY Incyte UBS
1/3/19	Upgrades	Neutral Buy	X
INCY Incyte Guggenheim
10/22/18	Upgrades	Outperform Strong Buy	X
INCY Incyte Raymond James
10/1/18	Initiated	Neutral	X
INCY Incyte Cantor Fitzgerald
$73
9/25/18	Initiated	Mkt Perform	X
INCY Incyte Leerink Partners
8/15/18	Upgrades	Sec Perform Outperform	X
INCY Incyte RBC Capital Mkts
8/1/18	Downgrades	Mkt Outperform Mkt Perform	X
INCY Incyte JMP Securities
7/13/18	Downgrades	Overweight Eq-Weight	X
INCY Incyte Morgan Stanley
6/26/18	Downgrades	Outperform Sec Perform	X
INCY Incyte RBC Capital Mkts
6/11/18	Upgrades	In-line Outperform	X
INCY Incyte Evercore ISI
4/9/18	Reiterated	Outperform	X
INCY Incyte Credit Suisse
$145 $78
4/9/18	Downgrades	Buy Hold	X
INCY Incyte Gabelli & Co
4/5/18	Reiterated	Overweight	X
INCY Incyte Barclays
$165 $135

INCY Incyte Corporation

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.